Red blood cell fatty acid patterns and acute coronary syndrome

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Shearer, Gregory C ^a   Pottala, James V ^a   Spertus, John A ^b   Harris, William S ^a  

^a SANFORD RESEARCH   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; DOCOSATETRAENOIC ACID; EICOSADIENOIC ACID; FATTY ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; ICOSATRIENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; OLEIC ACID; PALMITIC ACID; PALMITOLEIC ACID; POLYUNSATURATED FATTY ACID; STEARIC ACID; TRANS FATTY ACID; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; CASE CONTROL STUDY; COMPARATIVE STUDY; ERYTHROCYTE MEMBRANE; GAS CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ACUTE CORONARY SYNDROME; ADULT; AGED; CASE-CONTROL STUDIES; CHROMATOGRAPHY, GAS; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; FATTY ACIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 65549152876     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005444     Document Type: Article

References (42)

1. Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105: 310-315.
2. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, et al. (2004) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 173: 381-391.
3. Chambless LE, Folsom AR, Sharrett AR, Sorlie P, Couper D, et al. (2003) Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 56: 880-890.
4. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR (2008) C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction. The Reynolds Risk Score for Men. Circulation.
5. Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. Jama 297: 611-619.
6. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117: 743-753.
7. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847.
8. Vasan RS (2006) Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113: 2335-2362.
9. Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115: 928-935.
10. Cook NR (2008) Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 54: 17-23.
11. Lloyd-Jones DM, Liu K, Tian L, Greenland P (2006) Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease. Ann Intern Med.
12. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, et al. (2006) An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 166: 1368-1373.
13. Block RC, Harris WS, Reid KJ, Sands SA, Spertus JA (2007) EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis.
14. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, et al. (2002) Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 346: 1113-1118.
15. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, et al. (1995) Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. Jama 274: 1363-1367.
16. Lemaitre RN, King IB, Raghunathan TE, Pearce RM, Weinmann S, et al. (2002) Cell membrane trans-fatty acids and the risk of primary cardiac arrest. Circulation 105: 697-701.
17. Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, et al. (2004) Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation 110: 1645-1649.
18. Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36: 959-969.
19. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, et al. (2002) ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40: 1366-1374.
20. Pitt B, Loscalzo J, Ycas J, Raichlen JS (2008) Lipid levels after acute coronary syndromes. J Am Coll Cardiol 51: 1440-1445.
21. Harris WS (2007) Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Pharmacol Res 55: 217-223.
22. Harris WS (2006) The omega-6/omega-3 ratio and cardiovascular disease risk: uses and abuses. Curr Atheroscler Rep 8: 453-459.
23. Lands WE (1995) Long-term fat intake and biomarkers. Am J Clin Nutr 61: 721S-725S.
24. Greenland P (2008) Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina, R. B. D'Agostino Sr, R. B. D'Agostino Jr, R. S. Vasan, Statistics in Medicine (DOI: 10.1002/sim.2929). Stat Med 27: 188-190.
25. Pencina MJ, D' Agostino RB S, D'Agostino RB J, Vasan RS (2008) Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172.
26. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159: 882-890.
27. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36.
28. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843.
29. Willett WC (2006) Trans fatty acids and cardiovascular disease-epidemiological data. Atheroscler Suppl 7: 5-8.
30. Marcel YL, Christiansen K, Holman RT (1968) The preferred metabolic pathway from linoleic acid to arachidonic acid in vitro. Biochim Biophys Acta 164: 25-34.
31. Koshkin V, Dunford HB (1998) Reaction of prostaglandin endoperoxide synthase with cis,cis-eicosa-11,14-dienoic acid. J Biol Chem 273: 6046-6049.
32. Harris WS, Von Schacky C (2004) The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med 39: 212-220.
33. Harris WS, von Schacky C (2008) Omega-3 Fatty Acids, Acute Coronary Syndrome, and Sudden Death. Current Cardiovascular Risk Reports 2: 161-166.
34. Jurand J, Oliver MF (1970) Effects of acute myocardial infarction and of noradrenaline infusion on fatty acid composition of serum lipids. Atherosclerosis 11: 157-170.
35. Kark JD, Manor O, Goldman S, Berry EM (1995) Stability of red blood cell membrane fatty acid composition after acute myocardial infarction. J Clin Epidemiol 48: 889-895.
36. Maidment CG, Jones SP, Lea EJ (1988) Changes in platelet membrane fatty acids after myocardial infarction. Atherosclerosis 74: 9-14.
37. Ma DW, Seo J, Switzer KC, Fan YY, McMurray DN, et al. (2004) n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research. J Nutr Biochem 15: 700-706.
38. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, et al. (2006) n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 84: 5-17.
39. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, et al. (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105: 1897-1903.
40. Niu K, Hozawa A, Kuriyama S, Ohmori-Matsuda K, Shimazu T, et al. (2006) Dietary long-chain n-3 fatty acids of marine origin and serum C-reactive protein concentrations are associated in a population with a diet rich in marine products. Am J Clin Nutr 84: 223-229.
41. Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, et al. (2006) Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 91: 439-446.
42. Sekikawa A, Curb JD, Ueshima H, El-Saed A, Kadowaki T, et al. (2008) Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol 52: 417-424.